tbuckley/cabot-search huggingface dataset:
Abstract 14693: Sodium Hydrosulfide in the Setting of Cardioplegia and Cardiopulmonary Bypass in the Rat Model Reduces Ischemia-Reperfusion Injury
Authors: Chin Siang Ong, Yilin Ong, Duc Thang Vu, Min Zin Oo, Abdul Jalil Rufaihah, Ervin Marquez Ocampo, Theodoros Kofidis
Journal: Circulation (2016)

Introduction:  Sodium hydrosulfide (NaHS) has been shown to be a promising cardioprotective agent against ischemia-reperfusion injury, but its use as a component of cardioplegia in cardiopulmonary bypass (CPB) is untested. We investigated the potential cardioprotective effects of NaHS added to cardioplegia solution, in rats in cardiac arrest on CPB.   Methods:  Adult male Wistar rats (n=16) were placed on CPB and underwent 30 minutes of aortic cross-clamp (AoX)/ischemia, followed by 1 hour of reperfusion. Rats in the treatment group (n=8) received 40uM of NaHS in the cardioplegia solution, rats in the control group (n=8) did not. Hemodynamic parameters were measured intraoperatively and blood samples were collected at baseline, before and after AoX, and after weaning off CPB. Hearts were harvested at the end of the procedure.   Results:  The dP/dT max, indicative of systolic function, was better preserved in treatment groups post-CPB (32.7% decrease vs. 56.8% decrease from baseline) (p   Conclusions:  NaHS in cardioplegia solution significantly improves systolic function, diastolic function and ATP utilisation (which in turn results in improved hemodynamic parameters). It is superior to plain cardioplegia in reducing myocardial ischemia-reperfusion injury in the rat CPB and cardiac arrest model.
Bortezomib for Neuromyelitis Optica Spectrum Disorder
Authors: Jennifer Taylor, Sarosh R. Irani
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
P2.03a-065 Lack of Drug-Drug Interaction (DDI) between Necitumumab and Gemcitabine or Cisplatin: A Phase 2, Open-Label, Nonrandomized Study
Authors: Archana Chaudhary, Grace Chao, Fadi Braiteh, Michael Gordon, James Lee, Patricia Lorusso, Coleman Obasaju, Johan Wallin
Journal: Journal of Thoracic Oncology (2017)
Activation of the STING-Dependent Type I Interferon Response Reduces Microglial Reactivity and Neuroinflammation
Authors: Vidhu Mathur, Ritwik Burai, Ryan T. Vest, Liana N. Bonanno, Benoit Lehallier, Macy E. Zardeneta, Karishma N. Mistry, Danny Do, Samuel E. Marsh, Edsel M. Abud, Mathew Blurton-Jones, Lingyin Li, Hilal A. Lashuel, Tony Wyss-Coray
Journal: Neuron (2017)
Optimal cutoff of histological response by neoadjuvant chemotherapy for gastric cancer
Authors: K. Hara, T. Hayashi, H. Osakabe, M. Nakazono, S. Nagasawa, Y. Kumazu, T. Yamada, Y. Rino, M. Masuda, T. Ogata, T. Yoshikawa
Journal: Annals of Oncology (2017)
Abstract 382: Cell Type-specific Fibroblast Growth Factor Receptors That are Regulated in Human Heart Disease
Authors: Angela K Peter, Darrian N Bugg, Christopher D Ozeroff, Michel Chonchol, Amrut V Ambardekar, Rahul Kakkar, Leslie A Leinwand
Journal: Circulation Research (2016)

Chronic kidney disease (CKD) is characterized by increased serum levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23), the development of left ventricular hypertrophy, and increased risk of mortality due to cardiovascular disease. The FGF receptors (FGFRs) responsible for facilitating the effect of FGF23 on the heart and the expression patterns of FGFRs in the different cell types in the heart remain largely uncharacterized. We hypothesized that cardiomyocytes express a different FGFR profile than cardiac fibroblasts and that this differential expression profile could contribute to cell type-specific responses to FGF23. We measured FGFR mRNA levels at baseline and following pro-hypertrophic growth factor stimulation in isolated adult rat ventricular cardiomyocytes (ARVMs), neonatal rat ventricular cardiomyocytes (NRVMs), and neonatal rat ventricular fibroblasts (NRVFs). At baseline, NRVMs expressed predominantly FGFR1 but also expressed FGFRs 2 and 3. In ARVMs, FGFRs 1 and 3 predominated while FGFRs 2 and 4 were expressed at very low levels. FGFRs in ARVMs and NRVMs were unchanged by growthfactor stimulation. At baseline, NRVFs expressed equal amounts of FGFRs 1, 2 and 3 which were all downregulated with FGF23 stimulation. To determine whether these results translated to human hearts, we examined the FGFR profile in a cohort of non-failing, hypertrophic cardiomyopathy (HCM), and ischemic cardiomyopathy (ICM) human patient samples. Compared to non-failing patients, we found FGFR2 was significantly increased in HCM patients and trended towards an increase in ICM patients. The cardiac FGFR2 profile matched the FGF23 profile. In addition, we found that FGFR4 was significantly down regulated in both ICM and HCM compared to non-failing patients. In conclusion, different cell types in the heart differ in their FGFR profiles at baseline. The FGFR profile does not change in NRVMs or ARVMs in response to FGF23 treatment, but the expression of FGFRs 1, 2, and 3 decrease in NRVFs in response to FGF23. HCM and ICM in humans is characterized by an increase in FGFR2 and FGF23 expression accompanied with a downregulation of FGFR4 expression. Modulating FGFRs in the myocardium may provide a novel therapeutic target in CKD patients.
Restaging Abdominopelvic Computed Tomography Before Surgery After Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
Authors: Hyo Jung Park, Jong Keon Jang, Seong Ho Park, In Ja Park, Jong Hoon Kim, Seunghee Baek, Yong Sang Hong
Journal: JAMA Oncology (2017)

This study examines the association of diagnostic yield and postsurgical recurrence-free survival with restaging abdominopelvic computed tomography performed before surgery after receiving chemoradiotherapy in patients with locally advanced rectal cancer.
Abstract 21137: Nationwide Trends and Outcomes of Mechanical Circulatory Support With and Without Therapeutic Hypothermia for In-Hospital Cardiac Arrest
Authors: Gabriel A Hernandez, Alejandro Lemor, Vanessa Blumer, Nish Patel, Nilesh Patel, Sandra V Chaparro, Carlos Alfonso
Journal: Circulation (2017)

Introduction: In-hospital cardiac arrest (IHCA) is associated with elevated morbidity and mortality. Despite advances in cardiopulmonary resuscitation (CPR), survival remains dismal. The use of mechanical circulatory support (MCS) and therapeutic hypothermia (TH) have shown to improve outcomes when compared to conventional CPR in selected patients with IHCA. Limited studies describe the use of TH in patients receiving MCS during IHCA and there is currently no evidence demonstrating benefit of MCS with TH over MCS at normothermia. Methods: Using the National Inpatient Database we identified patients with IHCA from 2004 to 2014. Using ICD-9 procedure codes, we identified the use of TH and MCS. Univariate and multivariate linear and logistic regression models were generated to identify specific outcomes and in-hospital mortality. Results: Of 1,073,093 patients that underwent in-hospital CPR during 2004 to 2014, 2.7% had MCS without TH, 0.84 % underwent TH without MCS and 0.1% underwent TH with MCS. Baseline characteristics for each group are shown in Table 1. In patients who underwent MCS alone, 90.6% had balloon pump, 6.1% had extracorporeal membrane oxygenator and 3.3% had peripheral ventricular assisted device. In this group, 48% underwent percutaneous coronary intervention (PCI) and 42.5% of patients survived to discharge with half of them being discharged home (52.2%) and 31.2% to a nursing home or facility. Of those who received TH without MCS, fewer patients underwent PCI (6.1%) and 28.8% survived to discharge (48.6% being discharge to nursing home or facility). Of those who underwent MCS and TH, 55.6% underwent PCI and 35.8% survived to discharge. Conclusions: Use of MCS was associated with better survival outcomes and higher rate of PCI, regardless of the use of TH. No significant difference in mortality was noted in patients with HT without MCS (28.8% compared to the overall sample 27%).
Mosaic pathogenic <i>HRAS</i> variant in a patient with nevus spilus with agminated Spitz nevi and parametrial-uterine rhabdomyosarcoma
Authors: K. Nemeth, S. Szabo, C.E. Cottrell, S.M. McNulty, A. Segura, O. Sokumbi, M. Browning, D.H. Siegel
Journal: British Journal of Dermatology (2017)
Reframing Consent for Clinical Research: A Function-Based Approach
Authors: Neal W. Dickert, Nir Eyal, Sara F. Goldkind, Christine Grady, Steven Joffe, Bernard Lo, Franklin G. Miller, Rebecca D. Pentz, Robert Silbergleit, Kevin P. Weinfurt, David Wendler, Scott Y. H. Kim
Journal: The American Journal of Bioethics (2017)

Although informed consent is important in clinical research, questions persist regarding when it is necessary, what it requires, and how it should be obtained. The standard view in research ethics is that the function of informed consent is to respect individual autonomy. However, consent processes are multidimensional and serve other ethical functions as well. These functions deserve particular attention when barriers to consent exist. We argue that consent serves seven ethically important and conceptually distinct functions. The first four functions pertain principally to individual participants: (1) providing transparency; (2) allowing control and authorization; (3) promoting concordance with participants' values; and (4) protecting and promoting welfare interests. Three other functions are systemic or policy focused: (5) promoting trust; (6) satisfying regulatory requirements; and (7) promoting integrity in research. Reframing consent around these functions can guide approaches to consent that are context sensitive and that maximize achievable goals.
Toward a balanced view of stress-adapted cognition
Authors: Willem E. Frankenhuis, Bruce J. Ellis
Journal: Behavioral and Brain Sciences (2017)

Abstract Pepper &amp; Nettle's paper exemplifies an emerging resistance against an exclusive focus on deficits in people who come from harsh environments. We extend their model by arguing for a perspective that includes not only contextually appropriate responses but also strengths – that is, enhanced mental skills and abilities. Such a well-rounded approach can be leveraged in education, jobs, and interventions.
Sex-specific impact of asthma during pregnancy on infant gut microbiota
Authors: Petya T. Koleva, Hein M. Tun, Theodore Konya, David S. Guttman, Allan B. Becker, Piush J. Mandhane, Stuart E. Turvey, Padmaja Subbarao, Malcolm R. Sears, James A. Scott, Anita L. Kozyrskyj
Journal: European Respiratory Journal (2017)

Asthma during pregnancy is associated with retardation of fetal growth in a sex-specific manner. Lactobacilli microbes influence infant growth. This study aimed to determine whether lactobacilli and other microbes are reduced in the gut of infants born to an asthmatic mother, and whether this differs by the sex of the infant.Mother-infant pairs (N=1021) from the Canadian Healthy Infant Longitudinal Development full-term cohort were studied. The abundance of infant faecal microbiota at 3-4 months, profiled by gene sequencing, was compared between both women with and without asthma treatment during pregnancy. Infant sex, maternal ethnicity, pre-pregnancy overweight and atopy status, birth mode, breastfeeding status and intrapartum antibiotic treatment were tested as covariates.Independent of birth mode and other covariates, male, Caucasian infants born to women with prenatal asthma harboured fewer lactobacilli in the gut at 3-4 months of age. If asthmatic mothers had pre-pregnancy overweight, the abundance of Lactobacillus in males was further reduced in the infant gut, whereas the microbiota of female infants was enriched with Bacteroidaceae Similar differences in infant gut microbial composition according to maternal prenatal asthma status were also more evident among women with food or environmental allergies.Gut lactobacilli were less abundant in male infants, but Bacteroidaceae were more abundant in female infants at 3-4 months of age, following maternal asthma during pregnancy.
Economic impact of palliative care among elderly cancer patients.
Authors: Wendi G. Lebrett, Eric Roeland, Andrew Bruggeman, Heidi Yeung, James Don Murphy
Journal: Journal of Clinical Oncology (2017)

91 Background: Randomized trials among advanced cancer patients demonstrate that early palliative care integration into usual oncology care reduces symptom burden, improves quality of life and caregiver outcomes, and may improve survival. The impact of palliative care on health economics remains poorly defined and reported cost savings are an unintentional consequence of providing care aligned with patient goals. This study determined the impact of palliative care on healthcare costs among elderly patients with advanced cancer. Methods: We conducted a matched case-control study among Medicare beneficiaries with metastatic lung, colorectal, breast and prostate cancers. We matched patients who received a palliative care consultation to similar patients who did not receive a palliative care consultation. To determine the economic impact of a palliative care consultation we compared costs between cases and controls before and after the palliative care intervention. Costs included inpatient, outpatient, home health care, hospice, and medical equipment, and were adjusted to 2011 dollars. Results: Among the 2,576 patients in this study the total healthcare costs per patient in the 30 days before palliative care consultation was balanced between palliative care ($12,881) and non-palliative care control patients ($12,335). Palliative care intervention reduced total healthcare costs after the intervention. The total cost of care per patient in the 120 days after palliative care exposure was $6,880 compared to $9,604 for controls (28% decrease; p &lt; 0.001). The economic effect of palliative care depended on timing of the consult. Palliative care consultation within 7 days of death decreased healthcare costs by $975, whereas palliative care consultation more than 4 weeks from death decreased costs by $5,362. Conclusions: This study demonstrates that palliative care has the capacity to substantially reduce healthcare expenditures among advanced cancer patients. Furthermore, the cost reduction depends on timing of the palliative care consult.
Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses
Authors: Tomonori Yaguchi, Asuka Kobayashi, Takashi Inozume, Kenji Morii, Haruna Nagumo, Hiroshi Nishio, Takashi Iwata, Yuyo Ka, Ikumi Katano, Ryoji Ito, Mamoru Ito, Yutaka Kawakami
Journal: Cellular and Molecular Immunology (2017)
Gluten sensitivities and the allergist: Threshing the grain from the husks
Authors: J. G. Burkhardt, A. Chapa‐Rodriguez, S. L. Bahna
Journal: Allergy (2017)

Abstract “Gluten sensitivity” has become commonplace among the public. Wheat allergy ( WA ) and celiac disease ( CD ) are well‐defined entities, but are becoming a fraction of individuals following a gluten‐free diet (GFD). Wheat allergy has a prevalence of &lt;0.5%. Wheat, specifically its omega‐5 gliadin fraction, is the most common allergen implicated in food‐dependent, exercise‐induced anaphylaxis. CD is a non‐IgE hypersensitivity to certain cereal proteins: gluten in wheat, secalin in rye, hordein in barley, and to a lesser extent avenin in oat. It is a rare disease, with an estimated prevalence that varied widely geographically, being higher in Northern Europe and the African Saharawi region than in South‐East Asia. In addition to suggestive symptoms, serologic testing has high diagnostic reliability and biopsy is a confirmatory procedure. Patients with CD have extra‐intestinal autoimmune comorbid conditions more frequently than expected. A third entity is nonceliac gluten sensitivity, which has been created because of the increasing number of subjects who claim a better quality of life or improvement of their variety of symptoms on switching to a GFD. The phenomenon is being fueled by the media and exploited by the industry. The lack of a specific objective test has been raising substantial controversy about this entity. Allergists and gastroenterologists need to pay attention to the multitudes of individuals who elect to follow a GFD. Many such subjects might have WA , CD , or another illness. Providing them with appropriate evaluation and specific management would be of great advantages, medically and economically.
Randomized controlled trial (RCT) of a dyadic yoga program for lung cancer patients undergoing radiotherapy and their family caregivers.
Authors: Kathrin Milbury, Smitha Mallaiah, Zhongxing X. Liao, Vickie Shannon, Claire Yang, Lorenzo Cohen
Journal: Journal of Clinical Oncology (2017)

125 Background: Thoracic radiation (RT) is associated with respiratory toxicities, which may reduce patients’ physical performance and their overall quality of life (QOL). Yoga therapy may buffer against disease and treatment-related sequelae. The purpose of this RCT is to establish feasibility and preliminary efficacy of a yoga intervention. Because family caregivers also report symptom burden (e.g., distress, sleep disturbances) we included them as active participants in this trial. Methods: Non-small cell lung cancer patients undergoing RT and their caregivers were randomized to a 15-session yoga or a waitlist control (WLC) group. Prior to RT initiation and randomization, both groups completed measures of QOL (SF-36 domains). Patients also completed the 6-minute walk test (6MWT) to measure physical performance. Dyads were reassessed at the last day of RT and then 3 months later. Results: We approached 47 eligible dyads of which 32 (68%) consented and 26 (81%) completed all assessments. Patients (mean age: 73 yrs., 63% female, 67% stage III) and caregivers (mean age: 62 yrs., 38% female, 63% spouses) completed a mean of 12 sessions, and 96% of them rated the program as “very useful”. Controlling for baseline levels and other relevant covariates, multilevel modeling revealed a clinically and statistically significant difference in patients’ 6MWT (yoga mean = 478m vs. WLC mean = 402m, d= 1.19; p &lt; .05) and clinically significant differences in the physical function, role performance and mental health domains of the SF-36. For caregivers, clinically significant improvements were found in vitality and role performance. Conclusions: Yoga therapy appears to be a feasible and beneficial supportive care strategy for lung cancer patients and caregivers. A larger efficacy trial with a more stringent control group is warranted. Clinical trial information: NCT02196844.
Disminución de la reutilización de instrumental médico estéril desechable en hospitales daneses tras la publicación de un informe que desaconsejaba esta práctica
Authors: M Christensen, M Meyer, O. B Jepsen
Journal: Eurosurveillance (1999)

La extension de la practica consistente en reutilizar instrumental medico esteril catalogado como 'de un solo uso' o ‘desechable’ ha sido objeto de un estudio que, recientemente, se ha llevado a cabo en 100 hospitales de Dinamarca, Finlandia, Noruega y Suecia (1). El mismo metodo se utilizo en otro estudio realizado hace dos anos en los hospitales daneses. Esto nos ha permitido comparar los resultados de los hospitales daneses que participaron en ambas encuestas, y valorar la repercusion del informe del primer estudio, que recomendaba no volver a utilizar instrumental desechable, tanto en la politica como en la practica hospitalaria.
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
Authors: Palanisamy Nallasamy, Srinivas Chava, Sumit S. Verma, Shruti Mishra, Santhi Gorantla, Don W. Coulter, Siddappa N. Byrareddy, Surinder K. Batra, Subash C. Gupta, Kishore B. Challagundla
Journal: Seminars in Cancer Biology (2017)
Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies
Authors: Tracey G. Simon, Lindsay Y. King, Dawn Q. Chong, Long H. Nguyen, Yanan Ma, Trang VoPham, Edward L. Giovannucci, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kathleen E. Corey, Hamed Khalili, Raymond T. Chung, Xuehong Zhang, Andrew T. Chan
Journal: Hepatology (2017)

Type 2 diabetes (T2D) is a risk factor for hepatocellular carcinoma (HCC). However, it is unknown whether T2D duration or additional metabolic comorbidities further contribute to HCC risk. From the Nurses' Health Study (NHS), 120,826 women were enrolled in 1980, and from the Health Professionals Follow‐up Study (HPFS), 50,284 men were enrolled in 1986 and followed through 2012. Physician‐diagnosed T2D was ascertained at baseline and updated biennially. Cox proportional hazards regression models were used to calculate age‐ and multivariable‐adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident HCC. Over 32 years of follow‐up (4,488,410 person‐years), we documented 112 cases of HCC (69 women, 43 men). T2D was associated with an increased HCC risk (multivariable HR, 4.59; 95% CI, 2.98‐7.07), as was an increasing T2D duration ( P trend &lt; 0.001). Compared to nondiabetics, the multivariable HRs for HCC were 2.96 (95% CI, 1.57‐5.60) for 0‐&lt;2 years; 6.08 (95% CI, 2.96‐12.50) for 2‐&lt;10 years; and 7.52 (95% CI, 3.88‐14.58) for ≥10 years. Increasing number of metabolic comorbidities (T2D, obesity, hypertension, and dyslipidemia) was associated with increased HCC risk ( P trend &lt; 0.001); compared to individuals without metabolic comorbidity, those with four metabolic comorbidities had an 8.1‐fold increased HCC risk (95% CI, 2.48‐26.7). In T2D, neither insulin use nor oral hypoglycemic use was significantly associated with HCC risk (HR, 2.04 [95% CI, 0.69‐6.09] and HR, 1.45 [95% CI, 0.69‐3.07], respectively). Conclusion : T2D is independently associated with increased risk for HCC in two prospective cohorts of U.S. men and women. This risk is enhanced with prolonged diabetes duration and with comorbid metabolic conditions, suggesting the importance of insulin resistance in the pathogenesis of HCC. (H epatology 2018;67:1797‐1806)